Our name and logo changed on February 1.
Please note that some materials on the site may not yet reflect this change.
We are pleased to share news with you that CF patients in British Columbia now have access to HyperSal® and Nebusal®.
As of December 1st, HyperSal® and Nebusal® hypertonic saline 7% are now listed by Pharmacare as an eligible benefit for CF patients. Hypertonic saline has been shown to help reduce pulmonary exacerbations, improve lung function in individuals with cystic fibrosis, and is considered a standard of care for the disease in many countries. Should you have specific questions on HyperSal® and Nebusal®, please contact your local CF clinic.
Cystic Fibrosis Canada continues to actively advocate for equitable access to therapies and will keep you updated on current issues.
Reviewed/updated: 2012-12-05
